Baxter International Inc vs Gogoro Inc — how do they compare? Baxter International Inc trades at $26.94 (market cap $14.27B), while Gogoro Inc trades at $2.51 (market cap $52.19M). The key difference: Baxter International Inc is far larger — about 273.4× Gogoro Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| BAX | GGR | |
|---|---|---|
Market Cap | $14.27B | $52.19M |
Sector | Health | Technology |
52-Week High | $28.35 | $7.50 |
52-Week Low | $15.80 | $2.55 |
Enterprise Value | $21.79B | $354.63M |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).
The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →